Rare Disease Market Access and Orphan Drug Commercialization
Join market access and commercialization executives from pharmaceutical and biotech companies with a focus on rare, genetic, and orphan diseases to explore the current commercial dynamics surrounding these unique products. This Summit evaluates market forces, their economic impact, and the implications for orphan drug market access – covering early stage commercialization efforts through pricing, reimbursement, and patient and market access considerations.
Top Reasons to Attend:
- Hear an update on the 21st Century Cures Act
- Learn strategies to enhance your patient-centered approach to product commercialization
- Discuss lessons learned between industry and advocacy partnerships
- Understand key pricing models and how to develop a cost effectiveness model for your product
- Gain insight from payers on how they manage orphan drug pricing and reimbursement and their perceptions on value in relation to price
- Dive into the mechanics of lobbying in the rare disease space
- Determine how to choose the right distribution model for market success
Testimonials from attendees of the 2015 Summit:
“A great overview of all the key challenges and differences to consider when developing and commercializing an orphan drug” – Janice Arnold, Director, Oncology, Daichi Sanhyo
“This was the most content-consistent meeting with excellent information exchange, consistent in quality delivery. The speakers and presentations were clear and valuable.” – Haya Taitel, Vice President, New Product Commercialization, Kadmon
Rare Disease
Industry Updates
